Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D

Vaccine

Volumn 27, Issue 41, 2009, Pages 5661-5666

  Stahl, Christina ^a,b   Unger, Lucia ^a,b   Mazuet, Christelle ^c   Popoff, Michel ^c   Straub, Reto ^a   Frey, Joachim ^b  

^a VETSUISSE FACULTY UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c INSTITUT PASTEUR   (France)

Author keywords

Botulinum neurotoxin; Horse; Recombinant vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTISERUM; BOTULINUM TOXIN; BOTULINUM TOXIN TYPE C; BOTULINUM TOXIN TYPE D; BOTULISM VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HEAVY CHAIN; HORSE; IMMUNE RESPONSE; INJECTION SITE EDEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, BACTERIAL; ANTITOXINS; BACTERIAL VACCINES; BOTULINUM TOXINS; BOTULISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HORSES; IMMUNIZATION, SECONDARY; INJECTIONS, SUBCUTANEOUS; MALE; MICE; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; VACCINES, SYNTHETIC;

EID: 68949204150     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.021     Document Type: Article

References (31)

1. Schiavo G., Matteoli M., and Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 80 2 (2000) 717-766
2. Gerber V., Straub R., and Frey J. Equine botulism and acute pasture myodystrophy: new soil-borne emerging diseases in Switzerland?. Schweiz Arch Tierheilkd 148 10 (2006) 553-559
3. Botulismus K.C. Zoonosebericht 2002. BVET-Magazin 3 (2003) 32
4. Galey F.D. Botulism in the horse. Vet Clin North Am Equine Pract 17 3 (2001) 579-588
5. Böhnel H., Wagner C., and Gessler F. Tonsils-place of botulinum toxin production: results of routine laboratory diagnosis in farm animals. Vet Microbiol 130 3-4 (2008) 403-409
6. Byrne M.P., and Smith L.A. Development of vaccines for prevention of botulism. Biochimie 82 9-10 (2000) 955-966
7. Smith L.A., and Rusnack J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 27 4 (2007) 303-318
8. Boles J., West M., Montgomery V., Tammariello R., Pitt M.L., Gibbs P., et al. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 47 8 (2006) 877-884
9. Clayton M.A., Clayton J.M., Brown D.R., and Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 63 7 (1995) 2738-2742
10. Byrne M.P., Smith T.J., Montgomery V.A., and Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 66 10 (1998) 4817-4822
11. Lee J.C., Hwang H.J., Sakaguchi Y., Yamamoto Y., Arimitsu H., Tsuji T., et al. C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine. Microbiol Immunol 51 4 (2007) 445-455
12. Woodward L.A., Arimitsu H., Hirst R., and Oguma K. Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infect Immun 71 May (5) (2003) 2941-2944
13. Arimitsu H., Lee J.C., Sakaguchi Y., Hayakawa Y., Hayashi M., Nakaura M., et al. Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum type C and D neurotoxins. Clin Diagn Lab Immunol 11 May (3) (2004) 496-502
14. Webb R.P., Smith T.J., Wright P.M., Montgomery V.A., Meagher M.M., and Smith L.A. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 25 21 (2007) 4273-4282
15. Frey J., Eberle S., Stahl C., Mazuet C., Popoff M., Schatzmann E., et al. Alternative vaccination against equine botulism (BoNT/C). Equine Vet J 39 6 (2007) 516-520
16. Hauser D., Eklund M.W., Kurazono H., Binz T., Niemann H., Gill M., et al. Nucleotide sequence of Clostridium botulinum C1 neurotoxin. Nucleic Acids Res 18 16 (1990) 4924
17. Binz T., Kurazono H., Popoff M.R., Eklund M.W., Sakaguchi G., Kozaki S., et al. Nucleotide sequence of the gene encoding Clostridium botulinum neurotoxin type D. Nucleic Acids Res 18 18 (1990) 5556
18. Tavallaie M., Chenal A., Gillet D., Pereira Y., Manich M., Gibert M., et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett 572 1-3 (2004) 299-306
19. European Pharmacopoeia. Botulinum antitoxin. 4th edition; 2002. p. 0085.
20. Centers for Disease Control and Prevention: Botulism in the U.S. and Canada, 1899-1996. Handbook for epidemiologists, clinicians, and laboratory workers (1998), Centers for Disease Control and Prevention, Atlanta, GA
21. Mason J.H., Steyn H.P., and Bisshop J.H. The immunization of bovines against lamsiekte. J S Afr Vet Med Assoc 9 (1938) 65-70
22. Jansen B.C., Knoetze P.C., and Visser F. The antibody response of cattle to Clostridium botulinum types C and D toxoids. Onderstepoort J Vet Res 43 4 (1976) 165-173
23. Gregory A.R., Ellis T.M., Jubb T.F., Nickels R.J., and Cousins D.V. Use of enzyme-linked immunoassays for antibody to types C and D botulinum toxins for investigations of botulism in cattle. Aust Vet J 73 2 (1996) 55-61
24. Steinman A., Chaffer M., Elad D., and Shpigel N.Y. Quantitative analysis of levels of serum immunoglobulin G against botulinum neurotoxin type D and association with protection in natural outbreaks of cattle botulism. Clin Vaccine Immunol 13 8 (2006) 862-868
25. Hunter L.C., and Poxton I.R. Systemic antibodies to Clostridium botulinum type C: do they protect horses from grass sickness (dysautonomia)?. Equine Vet J 33 (2001) 547-553
26. Fiock M.A., Cardella M.A., and Gearinger N.F. Studies on immunity to toxins of Clostridium botulinum IX: immunologic response of man to purified pentavalent ABCDE botulinum toxoid. J Immunol 90 (1963) 697-702
27. Steinman A., Galon N., Arazi A., Bar-Giora Y., and Shpigel N.Y. Cattle immune response to botulinum type D toxoid: results of a vaccination study. Vaccine 25 November (44) (2007) 7636-7640
28. Montgomery V.A., Makuch R.S., Brown J.E., and Hack D.C. The immunogenicity in humans of a botulinum type F vaccine. Vaccine 18 7-8 (2000) 728-735
29. Siegel L.S. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol 26 11 (1988) 2351-2356
30. Lindsey C.Y., Smith L.A., West M.W., Boles J.W., and Brown J.E. Evaluation of a botulinum fragment C-based ELISA for measuring the humoral immune response in primates. Biologicals 31 1 (2003) 17-24
31. Fiock M.A., Devine L.F., Gearinger N.F., Duff J.F., Wright G.G., and Kadull P.J. Studies on immunity to toxins of Clostridium botulinum. VIII. Immunological response of man to purified bivalent AB botulinum toxoid. J Immunol 88 (1962) 277-283